Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery87% of ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...

Nivolumab-AVD outperforms BV-AVD in efficacy and safety, offering a promising frontline option for OAs with advanced classic ...

Nivolumab-based combinations may therefore "offer clinicians and payers a therapeutic option for previously untreated advanced RCC that may reduce the substantial clinical and economic impacts in ...

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of ...

EFS rate at 18 months was also 20 percentage points higher among the patients who received nivolumab vs placebo (70% vs 50%), and more of the patients randomized to treatment with nivolumab plus ...

Findings also showed at 47 months, nivolumab plus ipilimumab statistically significantly reduced the risk of disease progression or death by 38% vs nivolumab monotherapy (HR, 0.62 [95% CI, 0.48-0. ...